325 research outputs found
Recent advances in desmoid tumor therapy
The desmoid tumor is a locally aggressive proliferative disease within the family of soft-tissue sarcomas. Despite its relatively good prognosis, the clinical management of desmoid tumors requires constant multidisciplinary evaluation due to its highly variable clinical behavior. Recently, active surveillance has being regarded as the appropriate strategy at diagnosis, as indolent persistence or spontaneous regressions are not uncommon. Here, we review the most recent advances in desmoid tumor therapy, including low-dose chemotherapy and treatment with tyrosine kinase inhibitors. We also explore the recent improvements in our knowledge of the molecular biology of this disease, which are leading to clinical trials with targeted agents
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
Background: Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods: Institutional registries across seven Italian reference centers were retrospectively reviewed and data of interest retrieved to identify patients with GIST who had received regorafenib from February 2013 to January 2021. The Kaplan–Meier method was used to estimate survival and the log-rank test to make comparisons. Results: Of a total of 152 patients with GIST, 49 were treated with standard dose, while 103 received personalized schedules. At a median follow-up of 36.5 months, median progression-free survival was 5.6 months [95% confidence interval (CI) 3.73-11.0 months] versus 9.7 months (95% CI 7.9-14.5 months) in the standard-dose and the personalized schedule groups, respectively [hazard ratio (HR) 0.51; 95% CI 0.34-0.75; P = 0.00052]. Median overall survival was 16.6 months (95% CI 14.1-21.8 months) versus 20.5 months (95% CI 15.0-25.4 months), respectively (HR 0.75; 95% CI 0.49-1.22; P = 0.16). Conclusions: Regorafenib-personalized schedules are commonly adopted in daily clinical practice of high-volume GIST expert centers and correlate with significant improvement of therapeutic outcomes. Therefore, regorafenib treatment optimization in patients with GIST may represent the best strategy to maximize long-term therapy
Treatment of glenohumeral instability in rugby players
Rugby is a high-impact collision sport, with
impact forces. Shoulder injuries are common and result
in the longest time off sport for any joint injury in rugby.
The most common injuries are to the glenohumeral joint
with varying degrees of instability. The degree of instability
can guide management. The three main types of instability
presentations are: (1) frank dislocation, (2) subluxations
and (3) subclinical instability with pain and clicking.
Understanding the exact mechanism of injury can guide
diagnosis with classical patterns of structural injuries. The
standard clinical examination in a large, muscular athlete
may be normal, so specific tests and techniques are needed
to unearth signs of pathology. Taking these factors into
consideration, along with the imaging, allows a treatment
strategy. However, patient and sport factors need to be also
considered, particularly the time of the season and stage
of sporting career. Surgery to repair the structural damage
should include all lesions found. In chronic, recurrent
dislocations with major structural lesions, reconstruction
procedures such as the Latarjet procedure yields better outcomes.
Rehabilitation should be safe, goal-driven and athlete-
specific. Return to sport is dependent on a number of
factors, driven by the healing process, sport requirements and extrinsic pressures
- …